Authors
Sabiha Gati, Michael J Ackerman, Aaron L Baggish, Jonathan H Kim, Benjamin D Levine, Martin Maron, Matthew Martinez, Sharlene M Day
Published in
Medicine and science in sports and exercise. Volume 58. Issue 12. Pages 2844-2851. Dec 01, 2026. Epub Nov 13, 2026.
Abstract
The updated AHA/ACC Scientific Statement on Clinical Considerations for Competitive Sports Participation for Athletes with Cardiovascular Conditions presents the clinical considerations for athletes with genetic cardiomyopathies, including hypertrophic, dilated, arrhythmogenic, and left ventricular hypertrabeculation. This ACSM Official Pronouncement complements the 2020 ACC/AHA Scientific Statement by providing athlete-specific context, practical guidance for shared decision-making, and genotype-informed risk assessment for competitive sports participation, moving away from blanket sports disqualifications. Sports participation recommendations for each condition are tailored to risk levels, symptomatology, and genotype. Regular follow-ups and close surveillance are advised. This evolving approach underscores the importance of individualized care, ongoing research, and the integration of new data to better inform shared decision-making on the risks and benefits of competitive sports in athletes with cardiomyopathies.
PMID:
43024813
Bibliographic data and abstract were imported from PubMed on 14 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0